Cyclacel Pharmaceuticals (CYCC) Competitors $12.33 +9.02 (+272.51%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$8.31 -4.02 (-32.61%) As of 07/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. NNVC, BCAB, CMMB, VYNE, AYTU, DARE, FNCH, RLMD, SLGL, and DRRXShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include NanoViricides (NNVC), BioAtla (BCAB), Chemomab Therapeutics (CMMB), VYNE Therapeutics (VYNE), Aytu BioPharma (AYTU), Dare Bioscience (DARE), Finch Therapeutics Group (FNCH), Relmada Therapeutics (RLMD), Sol-Gel Technologies (SLGL), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Its Competitors NanoViricides BioAtla Chemomab Therapeutics VYNE Therapeutics Aytu BioPharma Dare Bioscience Finch Therapeutics Group Relmada Therapeutics Sol-Gel Technologies DURECT Cyclacel Pharmaceuticals (NASDAQ:CYCC) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Which has more volatility and risk, CYCC or NNVC? Cyclacel Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Which has better valuation and earnings, CYCC or NNVC? NanoViricides has lower revenue, but higher earnings than Cyclacel Pharmaceuticals. NanoViricides is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclacel Pharmaceuticals$40K487.04-$11.21M-$839.58-0.01NanoViricidesN/AN/A-$8.29M-$0.70-2.09 Do insiders and institutionals hold more shares of CYCC or NNVC? 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor CYCC or NNVC? In the previous week, Cyclacel Pharmaceuticals had 17 more articles in the media than NanoViricides. MarketBeat recorded 21 mentions for Cyclacel Pharmaceuticals and 4 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.76 beat Cyclacel Pharmaceuticals' score of 0.09 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CYCC or NNVC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CYCC or NNVC more profitable? NanoViricides' return on equity of -87.90% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cyclacel PharmaceuticalsN/A -3,648.09% -155.99% NanoViricides N/A -87.90%-78.69% SummaryCyclacel Pharmaceuticals and NanoViricides tied by winning 6 of the 12 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.25M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-0.0120.2228.5719.58Price / Sales487.04289.98423.3593.43Price / CashN/A43.1536.0257.93Price / Book-0.217.568.135.54Net Income-$11.21M-$55.11M$3.24B$257.73M7 Day Performance230.56%3.81%0.16%-0.08%1 Month Performance141.06%11.60%5.95%8.09%1 Year Performance-97.06%-2.11%26.09%13.02% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals1.2412 of 5 stars$12.33+272.5%N/A-97.0%$5.25M$40K-0.0114Trending NewsGap UpHigh Trading VolumeNNVCNanoViricides0.3008 of 5 stars$1.38flatN/A-18.4%$22.18MN/A-1.9220News CoveragePositive NewsBCABBioAtla2.0305 of 5 stars$0.39+2.6%$5.00+1,195.3%-77.5%$21.97M$11M-0.3260CMMBChemomab Therapeutics2.7693 of 5 stars$1.15-0.9%$8.50+639.1%+5.5%$21.87MN/A-1.5120Gap UpVYNEVYNE Therapeutics2.9746 of 5 stars$1.29-9.5%$6.25+384.5%-42.7%$21.67M$500K-1.3030Positive NewsHigh Trading VolumeAYTUAytu BioPharma4.2725 of 5 stars$2.35-1.3%$10.00+325.5%-23.0%$21.41M$81M-3.26160DAREDare Bioscience1.8551 of 5 stars$2.40flat$12.00+400.0%-15.7%$21.24M$10K-14.1230News CoverageHigh Trading VolumeFNCHFinch Therapeutics Group0.7724 of 5 stars$13.00-0.6%N/A+707.0%$21.00MN/A-1.47190Positive NewsRLMDRelmada Therapeutics4.7417 of 5 stars$0.61-3.1%$5.00+719.4%-83.5%$20.91MN/A-0.2410Gap DownSLGLSol-Gel Technologies3.1757 of 5 stars$7.29-2.4%$40.00+448.7%-9.9%$20.80M$11.54M-1.5550Gap DownDRRXDURECT1.2114 of 5 stars$0.64-4.0%N/A-60.7%$20.70M$2.03M-4.2780Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies NanoViricides Competitors BioAtla Competitors Chemomab Therapeutics Competitors VYNE Therapeutics Competitors Aytu BioPharma Competitors Dare Bioscience Competitors Finch Therapeutics Group Competitors Relmada Therapeutics Competitors Sol-Gel Technologies Competitors DURECT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
